Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal,

Pierre-Marie Girard1,2, Nathalie Berthault1,2, Maria Kozlac1,2

  • 1Institut Curie CNRS INSERM UMR 3347 PSL Research University Orsay France.

Insights

Novel cancer therapies inspired by evolutionary ecology show promise. Long-term treatment with AsiDNA, a DNA repair inhibitor, induces a stable "alarm down" state in cancer cells, preventing resistance development.

Area of Science:

  • Evolutionary biology
  • Cancer research
  • Drug discovery

Background:

  • Conventional cancer treatments face limitations due to acquired resistance driven by Darwinian selection.
  • Ecological and evolutionary principles offer potential for novel therapeutic strategies against cancer.

Purpose of the Study:

  • To explore how Darwinian principles can guide cancer evolution towards non-resistant trajectories.
  • To investigate the effects of long-term exposure to the DNA repair inhibitor AsiDNA on cancer cells.

Main Methods:

  • Review of data demonstrating cancer cell evolution under specific selective pressures.
  • Analysis of AsiDNA's mechanism of action involving DNA-PK and PARP enzymes.
  • Observation of cancer cell response to long-term AsiDNA treatment, including NAD levels.

Main Results:

  • Long-term AsiDNA exposure induces a stable "alarm down" state in cancer cells, characterized by pathway down-regulation.
  • This treatment strategy does not generate resistant cancer clones, unlike conventional therapies.
  • AsiDNA overactivates "false" DNA damage signaling via DNA-PK and PARP, distinct from PARP inhibitors.

Conclusions:

  • AsiDNA acts as an agonist drug, promoting state-dependent tumor cell evolution by reducing their response to danger signals.
  • Evolutionary ecology principles can inform drug design to overcome treatment resistance in cancer therapies.
  • This approach offers a promising avenue for developing more effective and durable cancer treatments.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K